Stock Alert: Adagene (ADAG) Down 6.67% in Pre-Market Trading for August 5
Equities Staff Follow |Adagene Inc - ADR (NASDAQ:ADAG) has already dropped $-0.1 in early trading Friday.
After closing the previous trading session at $1.50, Adagene has moved 6.67% lower ahead of market open.
The company has decreased 17.72% over the last 5 days.
Today could shape up to be a busy day for Adagene investors.
For technical charts, analysis, and more on Adagene Inc - ADR visit the company profile.
Pre-market prices and movements as of 06:26:33 est.
About Adagene Inc - ADR
Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
To get more information on Adagene Inc - ADR and to follow the company's latest updates, you can visit the company's profile page here: Adagene Inc - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer